FDA Confirms 13 Cases of Progressive Multifocal Leukoencephalopathy in Patients Receiving Natalizumab (Tysabri) for Multiple Sclerosis
FDA reports 13 confirmed cases of progressive multifocal leukoencephalopathy from patients taking Tysabri
Read more